Author

Jungshin Park

Observed name: Jungshin Park.

Institution: SK Group (South Korea)

Observed institution: SK Group (South Korea)

ORCID: 0009-0004-2761-3306

Observed ORCID: 0009-0004-2761-3306

OpenAlex ID: A5042260986

A randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures

2025 · Sang Kun Lee, Peimin Yu, et al. · Epilepsia · 11

Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double‐blind, placebo‐controlled study in a multinational Asian population

2025 · Kensuke Kawai, Eunyeong Choe, et al. · Epilepsia · 2

Efficacy of adjunctive cenobamate by focal seizure subtypes: a randomized, double-blind, placebo-controlled, multicenter study in a multinational Asian population

2025 · Xintong Wu, Ling Chen, et al. · Seizure · 2

Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population

2026 · Sang Kun Lee, Peimin Yu, et al. · Epilepsia · 1

Long-Term Efficacy of Adjunctive Cenobamate by Focal Seizure Subtypes: Open-Label Extension of a Randomized Clinical Study in a Multinational Asian Population

2026 · Peimin Yu, Xintong Wu, et al. · Neurology and Therapy

Abstract 5816: A novel NTSR1-targeting diagnostic radioligand SKL35502 for noninvasive solid tumor imaging

2026 · Jungtae Na, Taeyun Lee, et al. · Cancer Research

Abstract 5817: A novel NTSR1-targeting alpha radiotherapeutic SKL35501 demonstrating potent anti-tumor efficacy in HCT116 colorectal tumor model

2026 · Jungtae Na, Taeyun Lee, et al. · Cancer Research

Works count: 7

Citation count: 16

H-index: 2

I10-index: 1